| scholarly article | Q13442814 |
| P50 | author | Jerome Robert | Q56858042 |
| P2093 | author name string | Vincent Jarlier | |
| Aurélie Chauffour | |||
| Baohong Ji | |||
| P2860 | cites work | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model | Q21144660 |
| Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts | Q24650581 | ||
| Role of individual drugs in the chemotherapy of tuberculosis | Q28138632 | ||
| Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice | Q28364123 | ||
| Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans | Q33938119 | ||
| In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. | Q34680628 | ||
| Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin | Q35635900 | ||
| Potent twice-weekly rifapentine-containing regimens in murine tuberculosis | Q35776635 | ||
| Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice | Q36095055 | ||
| Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease) | Q36295353 | ||
| Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis | Q36565562 | ||
| Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice | Q42286897 | ||
| Pharmacokinetics of rifapentine in children | Q42684220 | ||
| A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment | Q44014994 | ||
| Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium | Q64131862 | ||
| Development of rifapentine: the way ahead | Q77124255 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium ulcerans | Q141154 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1912-1916 | |
| P577 | publication date | 2008-04-07 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice | |
| P478 | volume | 52 |
| Q28538259 | Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease |
| Q28476689 | Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice |
| Q58879937 | Antimicrobial drugs for Buruli ulcer – Authors' reply |
| Q37811544 | Buruli Ulcer: Advances in Understanding Mycobacterium ulcerans Infection |
| Q29353675 | Buruli ulcer in traveler from Suriname, South America, to the Netherlands |
| Q35689285 | Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model |
| Q37544684 | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. |
| Q28265322 | Current treatment of atypical mycobacteriosis |
| Q37247677 | Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice |
| Q38384606 | Methods used in preclinical assessment of anti-Buruli ulcer agents: A global perspective |
| Q28552736 | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice |
| Q37539074 | Susceptibility Profiles of Mycobacterium ulcerans Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana |
| Q99633705 | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses |
| Q35625819 | Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? |
| Q64233651 | Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening |
| Q34483614 | Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection |
Search more.